Literature DB >> 32012224

Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.

Theodor Uden1, Alice Bertaina2, Jonas Abrahamsson3, Marc Ansari4, Adriana Balduzzi5, Jean-Pierre Bourquin6, Corinne Gerhardt7, Marc Bierings7, Henrik Hasle8, Arjan Lankester9, Kirsten Mischke1, Andrew S Moore10, Ian Nivison-Smith11, Anna Pieczonka12, Christina Peters13, Petr Sedlacek14, Dirk Reinhardt15, Jerry Stein16, Birgitta Versluys17, Jacek Wachowiak12, Leen Willems18, Martin Zimmermann1, Franco Locatelli2,19, Martin G Sauer1.   

Abstract

Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; children; relapse; second hematopoietic stem cell transplantation

Year:  2020        PMID: 32012224     DOI: 10.1111/bjh.16441

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.

Authors:  Rebecca Epperly; Aimee C Talleur; Ying Li; Sarah Schell; MaCal Tuggle; Jean-Yves Métais; Sujuan Huang; Deqing Pei; Cheng Cheng; Renee Madden; Ewelina Mamcarz; Swati Naik; Amr Qudeimat; Akshay Sharma; Ashok Srinivasan; Ali Suliman; Stephen Gottschalk; Brandon M Triplett
Journal:  Transplant Cell Ther       Date:  2022-02-11

2.  Somatic FOXC1 insertion mutation remodels the immune microenvironment and promotes the progression of childhood acute lymphoblastic leukemia.

Authors:  Yaping Wang; Xiaopeng Ma; Jie Huang; Xiaoyun Yang; Meiyun Kang; Xiaoyan Sun; Huimin Li; Yijun Wu; Heng Zhang; Yuting Zhu; Yao Xue; Yongjun Fang
Journal:  Cell Death Dis       Date:  2022-05-03       Impact factor: 9.685

3.  Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS.

Authors:  Akshay Sharma; Ying Li; Sujuan Huang; Aimee C Talleur; Ali Suliman; Amr Qudeimat; Ashok Srinivasan; Ewelina Mamcarz; Renee Madden; Cheng Cheng; Stephen Gottschalk; Brandon M Triplett
Journal:  Bone Marrow Transplant       Date:  2021-03-19       Impact factor: 5.174

Review 4.  Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

Authors:  Jochen Buechner; Ignazio Caruana; Annette Künkele; Susana Rives; Kim Vettenranta; Peter Bader; Christina Peters; André Baruchel; Friso G Calkoen
Journal:  Front Pediatr       Date:  2022-01-25       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.